We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress
Sign In
Advertise with Us
Abbott Diagnostics

Download Mobile App




Events

ATTENTION: Due to the CORONAVIRUS EPIDEMIC, certain events are being rescheduled for a later date or altogether cancelled. Please check with the event organizer or website prior to planning for any forthcoming event.
19 May 2020 - 22 May 2020

Biological Fingerprint Identifies Leiomyomatosis and Renal Cell Cancer

By LabMedica International staff writers
Posted on 31 May 2011
Print article
A diagnostic test involves screening tumor samples for a particular molecular fingerprint unique to leiomyomatosis and renal cell cancer (HLRCC).

A protein modification induced by FH deficiency (due to an over-abundance of fumarate) was identified by scientists at the Henry Wellcome Building for Molecular Physiology, University of Oxford (United Kingdom). This alteration is unique to HLRCC and can be used as a biomarker–a biological 'fingerprint' to identify tumors caused by this mechanism.

The disorder is caused by mutations, which may be inherited, in a gene responsible for the production of an enzyme known as fumarate hydratase (FH). This leads to an accumulation within cells of fumarate, which promotes the development of cancer cells.

Screening cases of papillary renal cell cancer using the new test allows scientists to identify undiagnosed cases of HLRCC for genetic testing. The team that developed the test believes that it should be applied to all cases of papillary renal cell cancer to identify those with FH mutations, allowing advice to be provided to their families on their own relative risks of developing the disorder and associated kidney cancer.

Hereditary leiomyomatosis and renal cell cancer (HLRCC) is a disorder which causes the development of benign but often painful tumors in the skin and, in females, in the uterus. Between one in six and one in ten people affected by the disorder will go on to develop an aggressive form of kidney cancer called papillary renal cell cancer. The condition often strikes people in their twenties.

Dr. Lesley Walker, director of cancer information at Cancer Research UK (London, United Kingdom), said: "Tests like this can also help us to identify other patients with the same mutation, paving the way for the development of targeted treatments for specific groups of patients. This approach is called stratified medicine and many scientists now believe it could revolutionize cancer treatment in the future."

Related Links:

Cancer Research UK
Henry Wellcome Building for Molecular Physiology, University of Oxford






Print article

Channels

Lab Tech.

view channel
Image: Ultra-fast Cycling for Multiplexed Cellular Fluorescence Imaging (Photo courtesy of Massachusetts General Hospital Research Institute).

Ultra-Fast Cycling for Multiplexed Cellular Fluorescence Imaging

In the treatment of tumors, microenvironment plays an important role. It often contains immune cells that are so changed that they promote tumor growth. Until now, analyses of these dynamic changes with... Read more
Copyright © 2000-2020 Globetech Media. All rights reserved.